1. Home
  2. LPTX vs FRD Comparison

LPTX vs FRD Comparison

Compare LPTX & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • FRD
  • Stock Information
  • Founded
  • LPTX 2011
  • FRD 1965
  • Country
  • LPTX United States
  • FRD United States
  • Employees
  • LPTX N/A
  • FRD N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • FRD Steel/Iron Ore
  • Sector
  • LPTX Health Care
  • FRD Industrials
  • Exchange
  • LPTX Nasdaq
  • FRD Nasdaq
  • Market Cap
  • LPTX 119.6M
  • FRD 122.0M
  • IPO Year
  • LPTX N/A
  • FRD N/A
  • Fundamental
  • Price
  • LPTX $0.39
  • FRD $15.54
  • Analyst Decision
  • LPTX Buy
  • FRD
  • Analyst Count
  • LPTX 3
  • FRD 0
  • Target Price
  • LPTX $8.50
  • FRD N/A
  • AVG Volume (30 Days)
  • LPTX 321.2K
  • FRD 15.8K
  • Earning Date
  • LPTX 05-12-2025
  • FRD 02-07-2025
  • Dividend Yield
  • LPTX N/A
  • FRD 1.04%
  • EPS Growth
  • LPTX N/A
  • FRD N/A
  • EPS
  • LPTX N/A
  • FRD 0.81
  • Revenue
  • LPTX N/A
  • FRD $447,616,000.00
  • Revenue This Year
  • LPTX N/A
  • FRD N/A
  • Revenue Next Year
  • LPTX N/A
  • FRD N/A
  • P/E Ratio
  • LPTX N/A
  • FRD $19.02
  • Revenue Growth
  • LPTX N/A
  • FRD N/A
  • 52 Week Low
  • LPTX $0.39
  • FRD $13.40
  • 52 Week High
  • LPTX $4.79
  • FRD $19.52
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 18.56
  • FRD 46.44
  • Support Level
  • LPTX $0.40
  • FRD $14.93
  • Resistance Level
  • LPTX $0.46
  • FRD $15.94
  • Average True Range (ATR)
  • LPTX 0.03
  • FRD 0.68
  • MACD
  • LPTX 0.06
  • FRD -0.15
  • Stochastic Oscillator
  • LPTX 0.00
  • FRD 31.61

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

Share on Social Networks: